Captodiame

Jump to navigation Jump to search
Captodiame
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H29NS2
Molar mass359.594 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Captodiame

Articles

Most recent articles on Captodiame

Most cited articles on Captodiame

Review articles on Captodiame

Articles on Captodiame in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Captodiame

Images of Captodiame

Photos of Captodiame

Podcasts & MP3s on Captodiame

Videos on Captodiame

Evidence Based Medicine

Cochrane Collaboration on Captodiame

Bandolier on Captodiame

TRIP on Captodiame

Clinical Trials

Ongoing Trials on Captodiame at Clinical Trials.gov

Trial results on Captodiame

Clinical Trials on Captodiame at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Captodiame

NICE Guidance on Captodiame

NHS PRODIGY Guidance

FDA on Captodiame

CDC on Captodiame

Books

Books on Captodiame

News

Captodiame in the news

Be alerted to news on Captodiame

News trends on Captodiame

Commentary

Blogs on Captodiame

Definitions

Definitions of Captodiame

Patient Resources / Community

Patient resources on Captodiame

Discussion groups on Captodiame

Patient Handouts on Captodiame

Directions to Hospitals Treating Captodiame

Risk calculators and risk factors for Captodiame

Healthcare Provider Resources

Symptoms of Captodiame

Causes & Risk Factors for Captodiame

Diagnostic studies for Captodiame

Treatment of Captodiame

Continuing Medical Education (CME)

CME Programs on Captodiame

International

Captodiame en Espanol

Captodiame en Francais

Business

Captodiame in the Marketplace

Patents on Captodiame

Experimental / Informatics

List of terms related to Captodiame

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Captodiame (INN), also known as captodiamine, is an antihistamine sold under the trade names Covatine, Covatix, and Suvren which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine.[1]

A 2004 study suggested captodiame may be helpful in preventing benzodiazepine withdrawal syndrome in people discontinuing benzodiazepine treatment.[1]

In addition to its actions as an antihistamine, captodiamine has been found to act as a 5-HT2C receptor antagonist and σ1 receptor and D3 receptor agonist.[2] It produces antidepressant-like effects in rats.[2] However, captodiamine is unique among antidepressant-like drugs in that it increases brain-derived neurotrophic factor (BDNF) levels in the hypothalamus but not in the frontal cortex or hippocampus.[2] This unique action may be related to its ability to attenuate stress-induced anhedonia and corticotropin-releasing factor (CRF) signaling in the hypothalamus.[2]


See also

References

  1. 1.0 1.1 Mercier-Guyon C, Chabannes JP, Saviuc P (2004). "The role of captodiamine in the withdrawal from long-term benzodiazepine treatment". Curr Med Res Opin. 20 (9): 1347–55. doi:10.1185/030079904125004457. PMID 15383182. Free full text with registration
  2. 2.0 2.1 2.2 2.3 Ring RM, Regan CM (October 2013). "Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT2c receptor antagonism and sigma-1 receptor agonism". J. Psychopharmacol. (Oxford). 27 (10): 930–9. doi:10.1177/0269881113497614. PMID 23863923.


Template:Anxiolytics